Skip to main content
. 2023 Feb 1;15(3):918. doi: 10.3390/cancers15030918

Figure 8.

Figure 8

Downregulation of RIPK4 enhanced the effect of BRAFi on WM266.4 cell proliferation but does not A375. WM266.4 and A375 cells were transfected with RIPK4.si1 or neg.si RNA. After 48 h of transfection, cells were incubated with vemurafenib (PLX; 10 µM), dabrafenib (GSK; 10 nM), or DMSO, as a control, for 24 h. (a) The expression levels of the RIPK4, RB1, and CDK2 proteins were analyzed using Western blotting along with densitometry. GAPDH was used as a loading control. (b) Viability of the cells was assessed with MTT assay. Each bar represents the mean ± SD of three biological replicates. The samples were compared with the neg.si control treated with DMSO. * p < 0.05, ** p < 0.01.